CRISPR/Cas۹ Technology in glioblastomaCancer Treatment

Brain cancer has the highest mortality rate of all cancers. Gliomarefers to a tumor that is derived from brain glial stem cellsor progenitor cells and is the most common primary intracranialtumor. Due to its complex cellular components, as well as theaggressiveness and specificity of the pathogenic site of glioma,most patients with malignant glioma have poor prognoses followingsurgeries, radiotherapies, and chemotherapies. This cancercaused by the accumulation of genetic and epigenetic alterationsin ۲ types of genes: tumor suppressor genes (TSGs) andproto-oncogenes. According to reports, gain-of-function polymorphismsin a proto-oncogene and loss-of-function alterationsin tumor suppressor genes are the two main causes of glioblastoma.In recent years, an increasing amount of research has focusedon the use of CRISPR/Cas۹ gene-editing technology inthe treatment of glioma. To study tumor origins, development,and metastasis, CRISPR/Cas۹ can change genomes. In recentyears, tumor treatment research has increasingly employed thismethod. CRISPR/Cas۹ can treat cancer by removing genesor correcting mutations. CRISPR/Cas۹ may treat gene-leveltumors. Through the CRISPR/Cas۹ technique, the Nf۱, Pten,and Trp۵۳ genes responsible for glioblastoma and the Ptch۱gene accountable for medulloblastomas were knocked out. inaddition, CRISPR/Cas۹-based personalized and targeted medicinesmay shape tumor treatment. Precision medicine refers tomatching the right medicine to the right patients based on theirmolecular signatures. Therefore, a thorough understanding ofthe mechanism of tumorigenesis and drug resistance is essentialto precision medicine. Besides gene manipulation in the organism’slineage, presumptive tumorigenesis or tumor suppressorgenes have long been recognized as the benchmark for simulatingcarcinoma, especially brain tumors, in mice.

کلیدواژه ها:

Cancer ، glioma ، CRISPR/Cas۹ Technology ، precisionmedicine ، gene therapy